You are here

Xospata

Astellas Xospata comes up short again in bid to expand leukemia use

Astellas Xospata comes up short again in bid to expand leukemia use

Fierce Pharma

clinical trials

Flag link:

Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata

Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata

Pharmaforum

Flag link:

AACR: Astellas pads Xospata's AML lead with chemo-beating survival data

AACR: Astellas pads Xospata's AML lead with chemo-beating survival data

Fierce Pharma

acute myeloid leukemia

Flag link:

FDA stamps fast OK on Astellas' pioneering FLT3 AML drug gilteritinib, expanding on a record year for new approvals

FDA stamps fast OK on Astellas' pioneering FLT3 AML drug gilteritinib, expanding on a record year for new approvals

Endpoints

Flag link: